Cancer and sexual problems

Journal of Sexual Medicine

Volumn 7, Issue 1 PART 2, 2010, Pages 349-373

  Sadovsky, Richard ^a   Basson, Rosemary ^b   Krychman, Michael ^c,d,e   Morales, Antonio Martin ^f   Schover, Leslie ^g   Wang, Run ^h   Incrocci, Luca ⁱ  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Hoag Hospital   (United States)

^d Southern California Center for Sexual Health and Survivorship Medicine   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer and sexual problems; Cancer treatment and sexual problems; Chemotherapy and sexual problems; Radiation and sexual problems; Sexual problems

Indexed keywords

ANASTROZOLE; ANDROGEN; ANTIANDROGEN; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BCG VACCINE; BUSULFAN; CONJUGATED ESTROGEN; ESTROGEN; EXEMESTANE; GONADORELIN AGONIST; LETROZOLE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PLATINUM COMPLEX; PRASTERONE; PROSTAGLANDIN E1; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TAMOXIFEN; VITAMIN;

ACUPUNCTURE; ANDROGEN DEPRIVATION THERAPY; ANUS CANCER; ARTICLE; BLADDER CANCER; BRACHYTHERAPY; BREAST CANCER; BREAST SURGERY; CANCER RADIOTHERAPY; CHEMOSURGERY; CLINICAL TRIAL; COLORECTAL CANCER; COLOSTOMY; CRYOSURGERY; CYSTECTOMY; DRUG EFFICACY; DRUG SAFETY; DYSPAREUNIA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FEMALE SEXUAL DYSFUNCTION; GYNECOLOGIC CANCER; GYNECOLOGIC SURGERY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOGONADISM; IMPOTENCE; LIBIDO DISORDER; LOW LEVEL LASER THERAPY; MALE SEXUAL DYSFUNCTION; MENOPAUSAL SYNDROME; NEOPLASM; ORCHIECTOMY; ORGASM DISORDER; PATIENT COUNSELING; PELVIC FLOOR MUSCLE TRAINING; PENIS CANCER; PENIS PROSTHESIS; PREMATURE OVARIAN FAILURE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PSYCHOTHERAPY; PUBERTY DISORDERS; RADICAL HYSTERECTOMY; SEXUAL DYSFUNCTION; SEXUAL SATISFACTION; SIDE EFFECT; SOCIAL PSYCHOLOGY; TESTIS CANCER; URINARY DIVERSION; UTERINE CERVIX CANCER; VAGINAL DRYNESS; WATCHFUL WAITING; WEIGHT GAIN;

EID: 74049111836     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01620.x     Document Type: Article

References (295)

1. Zabora J, Loscalzo M, Berger AM, Portenoy RK, Weissman DE. Psychosocial consequences of advanced cancer. Principles and practice of palliative care and supportive oncology 2002, 749-61. In, eds., 2nd, edition, Philadelphia, PA, Lippincott Williams and Wilkins
2. Ofman U. " . . . And how are things sexually?" Helping patients adjust to sexual changes before, during and aftercancer treatment. Support Cancer Ther 2004, 1:243-7.
3. Park ER, Norris RL, Bober SL. Sexual health communication during cancer care. Cancer J 2009, 15:74-7.
4. Hordern AJ, Currow DC. A patient-centered approach to sexuality in the face of life-limiting illness. Med J Aust 2003, 179:S8-11. suppl
5. Wimberly SR, Carver CS, Laurenceu JP. Perceived partner reactions to diagnosis and treatment of breast cancer: Impact on psychosocial and psychosexual adjustment. J Consult Clin Psychol 2005, 73:300-11.
6. Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: How localized prostate cancer treatment affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009, 27:3916-22.
7. Wilt TJ, MacDonald R, Rutks I, Shamliyn TA, Taylor BC, Kane RL. Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008, 148:435-48.
8. Kakehi Y. Watchful waiting as a treatment option for localized prostate cancer in the PSA era. Jpn J Clin Oncol 2003, 33:1-5.
9. Gettman MT, Blute ML. Critical comparison of laparoscopic, robotic and open radical prostatectomy: Techniques, outcomes, and cost. Curr Urol Rep 2006, 7:193-9.
10. Siston AK, Knight SJ, Slimack NP, Chmiel JS, Nadler RB, Lyons TM, Kuzel TM, Moran EM, Sharifi R, Bennett CL. Veterans affairs cancer of the prostate outcomes study. Quality of life after a diagnosis of prostate cancer among men of lower socioeconomic status; results from the veterans affairs cancer of the prostate outcomes study. Urology 2003, 61:172-8.
11. Siegel T, Moul JW, Spevak M, Alvord WG, Costabile RA. The development of erectile dysfunction in men treated for prostate cancer. J Urol 2001, 165:430-5.
12. Arredondo SA, Downs TM, Lubeck DP, Pasta DJ, Silva SJ, Wallace KL, Carroll PR. Watchful waiting and health related quality of life for patients with localized prostate cancer: Data from CaPSURE. J Urol 2004, 172:1830-4.
13. Bacon CG, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 2001, 166:1804-10.
14. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Hohansson JE, Norlén BJ, Holmberg L. Scandinavian prostatic cancer group study number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002, 347:790-6.
15. Galbraith ME, Arechiga A, Ramierez J, Pedro LW. Prostate cancer survivors' and partners' self-reports of health-related quality of life, treatment symptoms, and marital satisfaction 2.5-5 years after treatment. Oncol Nurs Forum 2005, 32:E30-41.
16. Namiki S, Takegami M, Kakehi Y, Suzukamo Y, Fukuhara S, Arai Y. Analysis linking UCLA PCI with expanded prostate cancer index. Composite: An evaluation of health related quality of life in Japanese men with localized prostate cancer. J Urol 2007, 178:473-37. discussion 477
17. Katz G, Rodriguez R. Changes in continence and health-related quality of life after curative treatment and watchful waiting of prostate cancer. Urology 2007, 69:1157-60.
18. Bard H, Taylor CL. Sexual dysfunction and spousal communication in couples coping with prostate cancer. Psychooncology 2009, 18:735-46.
19. Gebhart F. Surgeon experience, technique influence radical prostatectomy outcomes: Urology Times. 2006, April
20. Kim ED, Scardino PT, Kadmon D, Slawin K, Nath RK. Interposition of sural nerve restores function of cavernous nerves resected during radical prostatectomy. J Urol 1999, 161:188-92.
21. Kim ED, Nath R, Slawin KM, Kadmon D, Miles BJ, Scardino PT. Bilateral nerve grafting during radical retropubic prostatectomy: Extended follow-up. Urology 2001, 58:983-7.
22. Porpiglia F, Ragni F, Terrone C, Renard J, Musso F, Grande S, Cracco C, Ghignone G, Scarpa RM. Is laparoscopic unilateral sural nerve grafting during radical prostatectomy effective in retaining sexual potency? BJU Int 2005, 95:1267-71.
23. Walsh PC, Donker PJ. Impotence following radical prostatectomy: Insight into etiology and prevention. J Urol 1982, 128:492-7.
24. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 1994, 152:1831-6.
25. Shrader-Bogen CL, Kjellberg JL, McPherson CP, Murray CL. Quality of life and treatment outcomes: Prostate carcinoma patients' perspectives after prostatectomy or radiation therapy. Cancer 1997, 79:1977-86.
26. Walsh PC, Donker PJ. Impotence following radical prostatectomy: Insight into etiology and prevention. J Urol 2002, 167:1005-10.
27. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Häggman M, Andersson SO, Spångberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlén BJ. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002, 347:781-9.
28. Schuessler WW, Schulam PG, Clayman RV, Kavoussi LR, Schuessler WW, Schulam PG, Clayman RV. Laparoscopic radical prostatectomy: Initial short-term experience. Urology 1997, 50:854-7.
29. Menon M, Shrivastava A, Tewari A, Sarle R, Hemal A, Peabody JO, Vallancien G. Laparoscopic and robot assisted radical prostatectomy: Establishment of a structured program and preliminary analysis of outcomes. J Urol 2002, 168:945-9.
30. Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999, 162:433-8.
31. Fulmer BR, Bissonette EA, Petroni GR, Theodorescu D. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: Comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. Cancer 2001, 91:2046-55.
32. Guillonneau B, Cathelineau X, Doublet JD, Baumert H, Vallancien G. Laparoscopic radical prostatectomy: Assessment after 550 procedures. Crit Rev Oncol Hematol 2002, 43:123-33.
33. Katz R, Salomon L, Hoznek A, de la Taille A, Vordos D, Cicco A, Chopin D, Abbou CC. Patient reported sexual function following laparoscopic radical prostatectomy. J Urol 2002, 168:2078-82.
34. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004, 172:2227-31.
35. Potosky AL, Davis WW, Hoffman RM. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The prostate cancer outcomes study. J Natl Cancer Inst 2004, 96:1358-67.
36. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA 2000, 283:354-60.
37. Ghavamian R, Knoll A, Boczko J, Melman A. Comparison of operative and functional outcomes of laparoscopic radical prostatectomy and radical retropubic prostatectomy: Single surgeon experience. Urology 2006, 67:1241-6.
38. Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000, 55:58-61.
39. Anastasiadis AG, Salomon L, Katz R, Hoznek A, Chopin D, Abbou CC. Radical retropubic versus laparoscopic prostatectomy: A prospective comparison of functional outcome. Urology 2003, 62:292-7.
40. Salomon L, Saint F, Anastasiadis AG, Sebe P, Chopin D, Abbou CC. Combined reporting of cancer control and functional results of radical prostatectomy. Eur Urol 2003, 44:656-60.
41. Link RE, Su LM, Sullivan W, Bhayani SB, Pavlovich CP. Health related quality of life before and after laparoscopic radical prostatectomy. J Urol 2005, 173:175-9.
42. Menon M, Shrivastava A, Tewari A. Laparoscopic radical prostatectomy: Conventional and robotic. Urology 2005, 66:101-4.
43. Menon M, Kaul S, Bhandari A, Shrivastava A, Tewari A, Hemal A. Potency following robotic radical prostatectomy: A questionnaire based analysis of outcomes after conventional nerve sparing and prostatic fascia sparing techniques. J Urol 2005, 174:2291-6.
44. Saranchuk JW, Kattan MW, Elkin E, Touijer AK, Scardino PT, Eastham JA. Achieving optimal outcomes after radical prostatectomy. J Clin Oncol 2005, 23:4146-51.
45. Penson DF, McLerran D, Feng Z. 5-year urinary and sexual outcomes after radical prostatectomy: Results from the prostate cancer outcomes study. J Urol 2005, 173:S40-4. Republished in 2008; 179(5 Suppl
46. Bianco FJ, Scardino PT, Eastham JA. Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function (" trifecta" ). Urology 2005, 66(5):83-94. Suppl
47. Curto F, Benijts J, Pansadoro A, Barmoshe S, Hoepffner JL, Mugnier C, Piechaud T, Gaston R. Nerve sparing laparoscopic radical prostatectomy: Our technique. Eur Urol 2006, 49:344-52.
48. Rassweiler J, Stolzenburg J, Sulser T. Laparoscopic radical prostatectomy-The experience of the German Laparoscopic Working Group. Eur Urol 2006, 49:113-9.
49. Menon M, Shrivastava A, Kaul S, Badani KK, Fumo M, Bhandari M, Peabody JO. Vattikuti Institute prostatectomy: Contemporary technique and analysis of results. Eur Urol 2007, 51:648-57.
50. Trabulsi EJ, Hassen WA, Touijer AK, Saranchuk JW, Guillonneau B. Laparoscopic radical prostatectomy: A review of techniques and results worldwide. Minerva Urol Nefrol 2003, 55:239-50.
51. Zippe C, Nandipati K, Agarwal A, Raina R. Sexual dysfunction after pelvic surgery. Int J Impot Res 2006, 18:1-18.
52. Miranda-Sousa AJ, Davila HH, Lockhart JL, Ordorica RC, Carrion RE. Sexual function after surgery for prostate or bladder cancer. Cancer Control 2006, 13:179-87.
53. Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus S, Liebert M, Moul JW, Tangen C, Thrasher JB, Thompson I. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol 2007, 178:597-601.
54. Mulhall JP, Secin FP, Guillonneau B. Artery sparing radical prostatectomy: Myth or reality? J Urol 2008, 179:827-31.
55. Ayyathurai R, Manoharan M, Nieder AM, Kava B, Soloway MS. Factors affecting erectile function after radical retropubic prostatectomy: Results from 1620 consecutive patients. BJU Int 2008, 101:833-6. Epub Jan 10, 2008
56. Donatucci C, Greenfield JM. Recovery of sexual function after prostate cancer treatment. Curr Opin Urol 2006, 16:444-8.
57. Ahlering TE, Eichel L, Skarecky D. Rapid communication: Early potency outcomes with cautery-free neurovascular bundle preservation with robotic laparoscopic radical prostatectomy. J Endourol 2005, 19:715-8.
58. Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol 2000, 164:1929.
59. Bhandary M, Menon M. Vattikuti Institute Prostatectomya (VIP) and current results. Arch Esp Urol 2007, 60:397-407.
60. Jayadevapp R, Bloom BS, Fomberstein SC, Wein AJ, Malkowicz SB. Health related quality of life and direct medical care cost in newly diagnosed younger men with prostate cancer. J Urol 2005, 174:1059-64.
61. Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, Kupelian PA. Defining sexual outcomes after treatment for localized prostate cancer. Cancer 2002, 95:1773-85.
62. Abouassaly R, Lane BR, Lakin MM, Klein EA, Gill IS. Ejaculatory urine incontinence after radical prostatectomy. Urology 2006, 68:1248.
63. Barnas JL, Pierpaoli S, Ladd P, Valenzuela R, Aviv N, Parker M, Waters WB, Flanigan RC, Mulhall JP. The prevalence and nature of orgasmic dysfunction after radical prostatectomy. BJU Int 2004, 94:603.
64. Lee J, Hersey K, Lee CT, Fleshner N. Climacturia following radical prostatectomy: Prevalence and risk factors. J Urol 2006, 176:2562.
65. Zippe CD, Pahlajani G. Vacuum erection devices to treat erectile dysfunction and early penile rehabilitation following radical prostatectomy. Curr Urol Rep 2008, 9:506-13.
66. Zelefsky MJ, Eid JF. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys 1998, 40:129-33.
67. DiBiase SJ, Wallner K, Tralins K, Sutlief S. Brachytherapy radiation doses to the neurovascular bundles. Int J Radiat Oncol Biol Phys 2000, 46:1301-7.
68. Merrick GS, Butler WM, Dorsey AT, Lief JH, Donzella JG. A comparison of radiation dose to the neurovascular bundles in men with and without prostate brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys 2000, 48:1069-74.
69. Merrick GS, Wallner K, Butler WM, Galbreath RW, Lief JH, Benson ML. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys 2001, 50:597-604.
70. Merrick GS, Butler WM, Wallner KE, Lief JH, Anderson RL, Smeiles BJ, Galbreath RW, Benson ML. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys 2002, 54:1055-62.
71. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Kurko BS, Lief JH, Allen ZA. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 62:437-47.
72. Fisch BM, Pickett B, Weinberg V, Roach M. Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer. Urology 2001, 57:955-9.
73. Kiteley RA, Lee WR, deGuzman AF, Mirzaei M, McCullough DL. Radiation dose to the neurovascular bundles or penile bulb does not predict erectile dysfunction after prostate brachytherapy. Brachytherapy 2002, 1:90-4.
74. Selek U, Cheung R, Lii M, Allen P, Steadham RE, Vantreese TR, Little DJ, Rosen II, Kuban D. Erectile dysfunction and radiation dose to penile base structures: A lack of correlation. Int J Radiat Oncol Biol Phys 2004, 59:1039-46.
75. Roach M, Winter K, Michalski J, Cox J, Purdy J Bosch W, Lin X, Shipley W. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys 2004, 60:1351-6.
76. Wernicke AG, Valicenti R, Dieva K, Houser C, Pequignot E. Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three-dimensional conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 60:1357-63.
77. Wright JL, Newhouse JH, Laguna JL, Vecchio D, Ennis RD. Localization of neurovascular bundles on pelvic CT and evaluation of radiation dose to structures putatively involved in erectile dysfunction after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004, 59:426-35.
78. Macdonald AG, Keyes M, Kruk A, Duncan G, Moravan W, Morris WJ. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important? Int J Radiat Oncol Biol Phys 2005, 63:155-63.
79. Mangar SA, Sydes MR, Tucker HL, Coffey J, Sohaib SA, Gianolini S, Webb S, Khoo VS, Dearnaley DP. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: Using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). Radiother Oncol 2006, 80:355-62.
80. Brown MW, Brooks JP, Albert PS, Poggi MM. An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma. Prostate Cancer Prostatic Dis 2007, 10:189-93.
81. van der Wielen GJ, Hoogeman MS, Dohle GR, van Putten WLJ, Incrocci L. Dose-volume parameters of the corpora cavernosa do not correlate with erectile dysfunction after external beam radiotherapy for prostate cancer: Results from a dose-escalation trial. Int J Radiat Oncol Biol Phys 2008, 71:795-800.
82. Solan AN, Cesaretti JA, Stone NN, Stock RG. There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009, 73:1468-74.
83. van der Wielen GJ, Mulhall JP, Incrocci L. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: A critical review. Radiother Oncol 2007, 84:107-13.
84. Incrocci L. Brachytherapy of prostate cancer and sexual dysfunction. UroOncology 2002, 2:107-12.
85. van der Wielen GJ, van Putten WLJ, Incrocci L. Sexual function after three-dimensional conformal radiotherapy for prostate cancer: Results from a dose-escalation trial. Int J Radiat Oncol Biol Phys 2007, 68:479-84.
86. Pinkawa M, Gagel B, Piroth MD, Fischedick K, Asadpour B, Kehl M, Klotz J, Eble MJ. Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol 2009, 55:227-36.
87. Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995, 45:616-23.
88. Beckendorf V, Hay M, Rozan R, Lagrange JL, N'Guyen T, Giraud B. Changes in sexual function after radiotherapy treatment of prostate cancer. Br J Urol 1996, 77:118-23.
89. Beard CJ, Propert KJ, Rieker PP, Clark JA, Kaplan I, Kantoff PW, Talcott JA. Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: A prospective multiinstitutional outcomes study. J Clin Oncol 1997, 15:223-9.
90. Borghede G, Hedelin H. Radiotherapy of localised prostate cancer. Analysis of late treatment complications. A prospective study. Radiother Oncol 1997, 43:139-46.
91. Turner SL, Adams K, Bull CA, Berry MP. Sexual dysfunction after radical radiation therapy for prostate cancer: A prospective evaluation. Urology 1999, 54:124-9.
92. Martinez A, Gonzalez J, Stromberg J, Edmundson G, Plunkett M, Gustafson G, Brown D, Yan D, Vicini F, Brabbins D. Conformal prostate brachytherapy: Initial experience of a phase I/II dose-escalating trial. Int J Radiat Oncol Biol Phys 1995, 33:1019-27.
93. Arterbery VE, Frazier A, Dalmia P, Siefer J, Lutz M, Porter A. Quality of life after permanent prostate implant. Surg Oncol 1997, 13:461-4.
94. Koutrouvelis PG. Three-dimensional stereotactic posterior ischiorectal space computerized tomography guided brachytherapy of prostate cancer: A preliminary report. J Urol 1998, 159:142-5.
95. Joly F, Brune D, Couette JE, Lesaunier F, Héron JF, Pény J, Henry-Amar M. Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. Ann Oncol 1998, 9:751-7.
96. Sharkey J, Chovnick SD, Behar RJ, Perez R, Otheguy J, Rabinowitz R, Steele J, Webster C, Donohue M, Solc Z, Huff W, Cantor A. Minimally invasive treatment for localized adenocarcinoma of the prostate: Review of 1048 patients treated with ultrasound-guided Palladium-103 brachytherapy. J Endourol 2000, 14:343-50.
97. Sánchez-Ortiz RF, Broderick GA, Rovner ES, Wein AJ, Whittington R, Malkowicz SB. Erectile function and quality of life after interstitial radiation therapy for prostate cancer. Int J Impot Res 2000, 12:18-24.
98. Kestin LL, Martinez AA, Stromberg JS, Edmundson GK, Gustafson GS, Brabbins DS, Chen PY, Vicini FA. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol 2000, 18:2869-80.
99. Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000, 47:1261-6.
100. Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001, 50:1235-42.
101. Stock RG, Kao J, Stone NN. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001, 165:436-9.
102. Arai Y, Aoki Y, Okubo K, Maeda H, Terada N, Matsuta Y, Maekawa S, Ogura K. Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: A prospective study. J Urol 2000, 164:1206-11.
103. Pierce LJ, Whittington R, Hanno PM, English W, Wein AJ, Goodman RL. Pharmacologic erection with intracavernosal injection for men with sexual dysfunction following irradiation: A preliminary report. Int J Radiat Oncol Biol Phys 1991, 21:1311-4.
104. Dubocq FM, Bianco FJ, Maralani SJ, Forman JD, Dhabuwala CB. Outcome analysis of penile implant surgery after external beam radiation for prostate cancer. J Urol 1997, 158:1787-90.
105. Zelefsky MJ, McKee AB, Lee H, Leibel SA. Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology 1999, 53:775-8.
106. Kedia S, Zippe CD, Agarwal A, Nelson DR, Lakin MM. Treatment of erectile dysfunction with sildenafil citrate (Viagra) after radiation therapy for prostate cancer. Urology 1999, 54:308-12.
107. Valicenti RK, Choi E, Lu JD, Hirsch IH, Mulholland SG, Gomella LG. Sildenafil citrate effectively reverses sexual dysfunction induced by three-dimensional conformal radiation therapy. Urology 2001, 57:769-73.
108. Weber DC, Bieri S, Kurtz JM, Miralbell R. Prospective pilot study of sildenafil for treatment of postradiotherapy erectile dysfunction in patients with prostate cancer. J Clin Oncol 1999, 17:3444-9.
109. Incrocci L, Koper PCM, Hop WCJ, Slob AK. Sildenafil citrate (Viagra) and erectile dysfunction following external-beam radiotherapy for prostate cancer. A randomized, double-blind, placebo-controlled, cross-over study. Int J Radiat Oncol Biol Phys 2001, 51:1190-5.
110. Incrocci L, Hop WCJ, Slob AK. Efficacy of sildenafil in an open-label study as a continuation of a double-blind study in the treatment of erectile dysfunction after radiotherapy of prostate cancer. Urology 2003, 62:116-20.
111. Incroci L, Slagter C, Slob AK, Hop WJC. A randomized, double-blind,placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis@) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2006, 66:439-44.
112. Incrocci L, Slob AK, Hop WC. Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: An open-label extension of a blinded trial. Urology 2007, 70:1190-3.
113. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002, 52:154-79.
114. Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M. Skeletal fracture associated with androgen suppression induced osteoporosis: The clinical incidence and risk factors for patients with prostate cancer. J Urol 2001, 166:1724-8.
115. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, Reimondo G, Mari M, Ardissone P, De Luca S, Fasolis G, Fontana D, Rossetti SR, Angeli A. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002, 167:2361-7.
116. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006, 91:1305-8.
117. Derweesh IH, DiBlasio CJ, Kincade MC, Malcolm JB, Lamar KD, Patterson AL, Kitabchi AE, Wake RW. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. Br J Urol 2007, 100:1060-5.
118. Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, Patterson AL. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol 2007, 14:3551-9.
119. Fowler FJ, McNaughton Collins M, Walker Corkery E, Elliott DB, Barry MJ. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 2002, 95:287-95.
120. DiBlasio CJ, Malcolm JB, Derweesh IH, Womack JH, Kincade MC, Mancini JG, Ogles ML, Lamar KD, Patterson AL, Wake RW. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. BJU Int 2008, 102:39-43.
121. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM. Quality-of-life outcomes after primary androgen deprivation therapy: Results from the prostate cancer outcomes study. J Clin Oncol 2001, 19:3750-3.
122. Basaria S, Lieb J, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol 2002, 56:779-86.
123. Traish AM, Guay AT. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med 2006, 3:382-407.
124. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: Putting IAD under the spotlight. BJU Int 2007, 99:19-22.
125. Incrocci L. Cancer and sexual function. Curr Urol 2007, 1:11-7.
126. Wiechno P, Demkow T, Kubiak K, Sadowska M, Kamińska J. The quality of life and hormonal disturbances in testicular cancer survivors in Cisplatin Era. Eur Urol 2007, 52:1448-55.
127. Nazareth I, Lewin J, King M. Sexual dysfunction after treatment for testicular cancer: Systemic review. J Psychosom Res 2001, 51:735-43.
128. Jonker-Pool G, Van de Wiel HB, Hoekstra HJ, Sleijfer DT, Van Driel MF, Van Basten JP, Schraffordt Koops H. Sexual functioning after treatment for testicular cancer-Review and meta-analysis of 36 empirical studies between 1975-2000. Arch Sex Behav 2001, 30:55-74.
129. Incrocci L, Hop WC, Wijnmaalen A, Slob AK. Treatment outcome, body image, and sexual functioning after orchiectomy and radiotherapy for stage I-II testicular seminoma. Int J Radiat Oncol Biol Phys 2002, 53:1165-73.
130. Lackner J, Schatzl G, Koller A, Mazal P, Waldhoer T, Marberger M, Kratzik C. Treatment of testicular cancer: Influence on pituitary-gonadal axis and sexual function. Urology 2005, 66:402-6.
131. Magelssen H, Brydøy M, Fosså SD. The effects of cancer and cancer treatments on male reproductive function. Nat Clin Pract Urol 2006, 3:312-22.
132. Pettus JA, Carver BS, Masterson T, Stasi J, Sheinfeld J. Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology 2009, 73:328-31. discussion 331-2. Epub Nov 20, 2008
133. Nord C, Bjøro T, Ellingsen D, Mykletun A, Dahl O. Gonadal hormones in long term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 2003, 44:322-8.
134. Gerl A, Muhlbayer D, Hansmann G, Mraz W, Hiddemann W. The impact of chemotherapy on Leydid cell function in long term survivors of germ cell tumors. Cancer 2001, 91:1297-303.
135. Adshead J, Khoubehi B, Wood J, Rustin G. Testicular implants and patient satisfaction: A questionnaire-based study of men after orchidectomy for testicular cancer. BJU Int 2001, 88:559-62.
136. Magelssen H, Haugen TB, von Düring V, Melve KK, Sandstad B, Fosså SD. Twenty years experience with semen cryopreservation in testicular cancer patients: Who needs it? EurUrol 2005, 48:779-85.
137. Jonker-Pool G, Hoekstra HJ, van Imhoff GW, Sonneveld DJ, Sleijfer DT, van Driel MF, Schraffordt Koops H, van de Wiel HB. Male sexuality after cancer treatment-Needs for information and support: Testicular cancer compared to malignant lymphoma. Patient Educ Couns 2004, 52:143-50.
138. Windahl T, Andersson SO. Combined laser treatment for penile carcinoma: Results after long-term followup. J Urol 2003, 169:2118.
139. van Bezooijen BPJ, Horenblas S, Meinhardt W, Newling DWW. Laser therapy for carcinoma in situ of the penis. J Urol 2001, 166:1670.
140. Romero FR, Romero KR, Mattos MA, Garcia CR, Fernandes Rde C, Perez MD. Sexual function after partial penectomy for penile cancer. Urology 2005, 66:1292-95.
141. Windahl T, Skeppner E, Anderson SO, Fugl-Meyer KS. Sexual function and satisfaction in men after laser treatment for penile carcinoma. J Urol 2004, 172:648-51.
142. Micali G, Nasca MR, Innocenzi D, Schwartz RA. Invasive penile carcinoma: A review. Dermatol Surg 2004, 30:311-20.
143. Stancik I, Höltl W. Penile cancer: Review of the recent literature. Curr Opin Urol 2003, 13:467-72.
144. Frimberger D, Hungerhuber E, Zaak D, Waidelich R, Hofstetter A, Schneede P. Penile carcinoma. Is Nd: YAG laser therapy radical enough? J Urol 2002, 168:2418.
145. Pietrzak P, Corbishley C, Watkin N. Organ-sparing surgery for invasive penile cancer: Early follow-up data. BJU Int 2004, 94:1253-57.
146. D'Ancona CAL, Botega NJ, Moraes C, Lavoura NS, Santos JK, Rodrigues- Netto N. Quality of life after partial penectomy for penile carcinoma. Urology 1997, 50:593-6.
147. Krueger H, McLean D, Williams D. Genitourinary cancers. Prog Exp Tumor Res 2008, 40:92-101.
148. Van der Aa MN, Steyerberg EW, Sen EF, Zwarthoff EC, Kirkels WJ, van der Kwast TH, Essink-Bot M. Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: A randomized comparison. BJU Int 2008, 101:1106-10.
149. Sighinolfi MC, Micali S, De Stefani S, Mofferdin A, Ferrari N, Giacometti M, Bianchi G. Bacille Calmette-Guérin intravesical instillation and erectile function: Is there a concern. Andrologia 2007, 39:51-4.
150. Gilbert SM, Wood DP, Dunn RL, Weizer AZ, Lee CT, Montie JE, Wei JT. Measuring health-related quality of life outcomes in bladder cancer patients using the bladder cancer index (BCI). Cancer 2007, 109:1756-62.
151. Madersbacher S, Studer UE. Contemporary cystectomy and urinary diversion. World J Urol 2002, 20:151-7.
152. Caffo O, Fellin G, Graffer U, Luciani L. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma: A survey by a self-administered questionnaire. Cancer 1996, 78:1089-97.
153. Henningsohn L, Steven K, Kallestrup EB, Steineck G. Distressful symptoms and well-being after radical cystectomy and othotopic bladder substitution compared with a matched control population. J Urol 2002, 168:168-75.
154. Zietman AL, Sacco D, Skowronski U, Gomery P, Kaufman DS, Clark JA, Talcott JA, Shipley WU. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: Results of a urodynamic and quality of life study on long-term survivors. J Urol 2003, 170:1772-6.
155. Nelles JL, Konety BR, Saigal C, Pace J, Lai J. Urologic Diseases in America Project. Urethrectomy following cystectomy for bladder cancer in men: Practice patterns and impact on survival. J Urol 2008, 180:1933-6.
156. Schover LR, Evans R, von Eschenbach AC. Sexual rehabilitation and male radical cystectomy. J Urol 1986, 136:1015-7.
157. Walsh P, Mostwin JL. Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique. Br J Urol 1984, 56:694-7.
158. Puppo P, Introini C, Bertolotto F, Naselli A. Potency preserving cystectomy with intrafascial prostatectomy for high risk superficial bladder cancer. J Urol 2008, 179:1727-32.
159. Nieuwenhuijzen JA, Meinhardt W, Horenblas S. Clinical outcomes after sexuality preserving cystectomy and neobladder (prostate sparing cystectomy) in 44 patients. J Urol 2005, 173:1314-7.
160. Stein JP, Hautmann RE, Penson D, Skinner DG. Prostate-sparing cystectomy: A review of the oncologic and functional outcomes. Contraindicated in patients with bladder cancer. Urol Oncol 2009, 27:466-72.
161. Zippe CD, Rupesh R, Massanyi EZ, Agarwal A, Jones JS, Ulchaker J, Klein EA. Sexual function after male radical cystectomy in a sexually active population. Urology 2004, 64:682-5.
162. Hekal IA, El-Bahnasawy MS, Mosbah A, El-Assmy A, Shaaban A. Recoverability of erectile function in post-radical cystectomy patients: Subjective and objective evaluations. Eur Urol 2009, 55:275-83.
163. Davila HH, Weber T, Burday D, Thurman S, Carrion R, Salup R, Lockhart JL. Total or partial prostate sparing cystectomy for invasive bladder cancer: Long-term implications on erectile function. BJU Int 2007, 100:1026-9.
164. Titta M, Tavolini IM, Moro FD, Cisternino A, Bassi P. Sexual counseling improved erectile rehabilitation after non-nerve-sparing radical retropubic prostatectomy or cystectomy-Results of a randomized prospective study. J Sex Med 2006, 3:267-73.
165. Gore JL, Saigal CS, Hanley JM, Schonlau M, Litwin MS. Urologic diseases in America project. Variations in reconstruction after radical cystectomy. Cancer 2006, 107:729-37.
166. Lee CT, Latini DM. Urinary diversion: Evidence-based outcomes assessment and integration into patient decision-making. BJU Int 2008, 102:1326-33.
167. Bjerre BD, Johansen C, Steven K. Sexological problems after cystectomy: Bladder substitution compared with ileal conduit diversion. A questionnaire study of male patients. Scand J Urol Nephrol 1998, 32:187-93.
168. Henningsohn L, Wijkstrom H, Dickman PW, Bergmark K, Steineck G. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol 2002, 62:215-25.
169. Kikuchi E, Horiguchi Y, Nakashima J, Ohigashi T, Oya M, Nakagawa K, Miyajima A, Murai M. Assessment of long-term quality of life using the FACT-BL questionnaires in patients with an ileal conduit, continent reservoir, or orthotopic neobladder. Jpn J Clin Oncol 2006, 36:712-6.
170. Studer UE, Burkhard FC, Schumacher M, Kessler TM, Thoeny H, Fleischmann A, Thalmann GN. Twenty years experience with an ileal orthotopic low pressure bladder substitute-Lessons to be learned. J Urol 2006, 176:161-6.
171. Frich PS, Kvestad CA, Angelsen A. Outcome and q1uality of life in patients operated on with radical cystectomy and three diffeent urinary diversion techniques. Scand J Urol Nephrol 2008, 23:1-5. ePublication ahead of print
172. Schover LR, von Eschenbach AC. Sexual function and female radical cystectomy: A case series. J Urol 1985, 134:465-8.
173. Zippe CD, Rupesh R, Shah AD, Massanyi EZ, Agarwal A, Ulchaker J, Jones S, Klein E. Female sexual dysfunction after radical cystectomy: A new outcome measure. Urology 2004, 63:1153-7.
174. Kessler TM, Studer UE, Burkhard FC. Increased proximal urethral sensory threshold after radical pelvic surgery in women. Neurourol Urodyn 2007, 26:208-12.
175. Bhatt A, Nandipati K, Dhar N, Ulchaker J, Jones S, Rackley R, Zippe C. Neurovascular preservation in orthotopic cystectomy: Impact on female sexual function. Urology 2006, 67:742-5.
176. Nandipati KC, Bhat A, Zippe CD. Neurovascular preservation in female orthotopic radical cystectomy significantly improves sexual function. Urology 2006, 67:185-6.
177. Volkmer BG, Schwend JE, Herkommer K, Simon J, Kufer R, Hautmann RE. Cystectomy and orthotopic ileal neobladder: The impact on female sexuality. J Urol 2004, 172:2353-7.
178. Arndt V, Merx H, Stegmaier C, Ziegler H, Brenner H. Restrictions in quality of life in colorectal cancer patients over three years after diagnosis: A population based study. Eur J Cancer 2006, 42:1848-57.
179. Hendren SK, O'Connor B, Liu M, Asano T, Cohen Z, Swallow CJ. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg 2005, 242:212-23.
180. Heriot AG, Tekkis PP, Fazio VW, Neary P, Lavery IC. Adjuvant radiotherapy is associated with increased sexual dysfunction in male patients undergoing resection for rectal cancer: A predictive model. Ann Surg 2005, 242:502-11.
181. Ameda K, Kakizaki H, Koyanagi T, Hirakawa K, Kusumi T, Hosokawa M. The long-term voiding function and sexual function after pelvic nerve-sparing radical surgery for rectal cancer. Int J Urol 2005, 12:256-63.
182. Camilleri-Brennan J, Steele RJC. Prospective analysis of quality of life and survival following mesorectal excision for rectal cancer. Br J Surg 2001, 88:1617-22.
183. Allal AS, Gervaz P, Gertsch P, Bernier J, Roth AD, Morel P, Bieri S. Assessment of quality of life in patients with rectal cancer treated by preoperative radiotherapy: A longitudinal prospective study. Int J Radiat Oncol Biol Phys 2005, 61:1129-35.
184. Marijnen Corrie AM, van de Velde Cornelis JH, Putter Hein, van den Brink Mandy, Maas Cornelis P, Martijn Hendrik, Rutten Harm J, Wiggers Theo, Kranenbarg Elma Klein, Leer Jan-Willem H, Stiggelbout Anne M. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 2005, 23:1847-58.
185. Krouse R, Grant M, Ferrell B, Dean G, Nelson R, Chu D. Quality of life outcomes in 599 cancer and non-cancer patients with colostomies. J Surg Res 2007, 138:79-87.
186. Pachler J, Wille-Jorgensen P. Quality of life after rectal resection for cancer, with or without permanent colostomy. Cochrane Database Syst Rev 2004, 3:CD004323.
187. Sprangers MA, te Velde A, Aaronson NK. The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Eur J Cancer 1999, 35:238-47.
188. Yost KJ, Hahn EA, Zaslavsky AM, Ayanian JZ, West DW. Predictors of health-related quality of life in patients with colorectal cancer. Health Qual Life Outcomes 2008, 6:66-76.
189. Çol C, Hasdemir O, Yalçin E, Yandakçi K, Tunç G, Kuçukpinar T. Sexual dysfunction after curative radical resection of rectal cancer in men: The role of extended systematic lymph-node dissection. Med Sci Monit 2006, 12:CR70-4.
190. Rosen FC, Cappellieri JC, Gendrano N. The International Index of Erectile Function (IIEF): A state-of-the-science review. Int J Impot Res 2002, 14:226-44.
191. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): Cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2005, 231:1-20.
192. Vironen JH, Kairaluoma M, Aalto AM, Kellokumpu IH. Impact of functional results on quality of life after rectal cancer surgery. Dis Colon Rectum 2006, 49:568-78.
193. Engel J, Kerr J, Schlesinger-Raab A, Eckel R, Sauer H, Hölzel D. Quality of life in rectal cancer patients: A four-year prospective study. Ann Surg 2003, 238:203-13.
194. Maas CP, Moriya Y, Steup WH, Klein Kranenbarg E, van de Velde CJH. A prospective study on radical and nerve-preserving surgery for rectal cancer in Netherlands. Eur Surg J Oncol 2000, 26:751-7.
195. Gosselink MP, Busschbach JJ, Dijkhuis CM, Stassen LP, Hop WC, Schouten WR. Quality of life after total mesorectal excision for rectal cancer. Colorectal Dis 2005, 8:15-22.
196. Mannaerts GHH, Schijven MP, Hendrikx A, Martijn H, Rutten HJT, Wiggers T. Urologic and sexual morbidity following multimodality treatment for locally advanced primary and locally recurrent rectal cancer. EJSO 2001, 27:265-72.
197. Breukink SO, van Driel MF, Pierie JPEN, Dobbins C, Wiggers T, Meijerink WJHJ. Male sexual function and lower urinary tract symptoms after laparoscopic total mesorectal excision. Int J Colorectal Dis 2008, 23:1199-205.
198. Liang JT, Lai HS, Lee PH. Laparascopic pelvice autonomic nerve-preserving surgery for patients with lower rectal cancer after chemordaiation therapy. Ann Surg Oncol 2007, 14:1285-7.
199. Sterk P, Shekarriz B, Günter S, Nolde J, Keller R, Bruch HP, Shekarriz H. Voiding and sexual dysfunction after deep rectal resection and total mesorectal excision: Prospective study on 52 patients. Int J Colorectal Dis 2005, 20:423-7.
200. Schmidt CE, Bestmann B, Küchler T, Longo WE, Kremer B. Ten-year historic cohort of quality of life and sexuality in patients with rectal cancer. Dis Colon Rectum 2005, 48:483-92.
201. Bonnel C, Parc YR, Pocard M, Dehni N, Caplin S, Parc R, Tiret E. Effects of preoperative radiotherapy for primary respectable rectal adenocarcinoma on male sexual and urinary function. Dis Colon Rectum 2002, 45:934-9.
202. Maurer CA, Z'Graggen K, Renzulli P, Schilling MK, Netzer P, Büchler MW. Total mesorectal excision preserves male genital function compared with conventional rectal cancer surgery. Br J Surg 2001, 88:1501-5.
203. Wexler A, Berson AM, Goldstone SE, Waltzman R, Penzer J, Maisonet OG, McDermott B, Rescigno JL. Invasive anal squamous-cell carcinoma in the HIV-positive patient: Outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum 2008, 51:73-81.
204. Karanes C, Nelson GO, Chitphakdithai P, Agura E, Ballen KK, Bolan CD, Porter DL, Uberti JP, King RJ, Confer DJ. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor program. Biol Blood Marrow Transplant 2008, 14:8-15.
205. Weissman IL, Shizuru JA. The origins of the identiicaiton and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat auktoimmune diseases. Blood 2008, 112:3543-53.
206. Schimmer AD, Ali V, Stewart K, Imrie K, Keating A. Male sexual function after autologous blood or marrow transplantation. Biol Blood Marrow Transplant 2001, 7:279-83.
207. Chatterjee R, Kottaridis PD, McGarrigle HH, Linch DC. Post-transplant complications: Management of erectile dysfunction by combination therapy with testostereone and sildenafil in recipients of high-dose therapy for haematological malignancies. Bone Marrow Transplant 2002, 29:607-10.
208. Schover LR. Premature ovarian failure and its consequences: Vasomotor symptoms, sexuality, and fertility. J Clin Oncol 2008, 10:753-8.
209. Yi JC, Syrjala KL. Sexuality after hematopoietic stem cell transplantation. Cancer J 2009, 15:57-64.
210. Tierney KD, Facione N, Padilla G, Blume K, Dodd M. Altered sexual health and quality of life in women prior to hematopoietic cell transplantation. Eur J Oncol Nurs 2007, 11:298-308.
211. Stratton P, Turner ML, Child R, Barrett J, Bishop M, Wayne AS, Pavletic S. Vulvovaginal chronic graft-versus-host disease with allogeneic hemtopoietic stem cell transplantation. Obstet Gynecol 2007, 110:1041-9.
212. Cohen A, Bekassy AN, Gaiero A, Faraci M, Zecca S, Tichelli A, Dini G. On behalf of the EBMT Paediatric and Late Effects Working Parties. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant 2008, 41:S43-48.
213. González Pérez P, Serrano-Pozo A, Franco-Macías E, Montes-Latorre E, Gómez-Aranda F, Campos T. Vincristine-induced acute neurotoxicity versus Guillain-Barré syndrome: A diagnostic dilemma. Eur J Neurol 2007, 14:826-8.
214. van der Wielen GJ, Mulhall JP, Incrocci L. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: A critical review. Radiother Oncol 2007, 84:107-13.
215. Critchley HO, Wallace WH. Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr 2005, 34:64-8.
216. Grigg AP, Underhill C, Russell J, Sale G. Peyronie's disease as a complication of chronic graft versus host disease. Hematology 2002, 7:165-8.
217. Nylander E, Wahlin YB, Lundskog B, Wahlin A. Letter to the Editor: Genital graft-versus-host disease in a male following allogeneic stem cell transplantation. Acta Derm Venereol 2007, 87:367-8.
218. Nelson CJ, Diblasio C, Kendirci M, Hellstrom W, Guhring P, Mulhall JP. The chronology of depression and distress in men with Peyronie's Disease. J Sex Med 2008, 5:1907-14.
219. Rosen R, Catania J, Lue T, Althof S, Henne J, Hellstrom W, Levine L. Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med 2008, 5:1977-84.
220. Watson M, Wheatley K, Harrison GA, Zittoun R, Gray RG, Goldstone AH, Burnett AK. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: Analysis of the MRC AML 10 Trial. Cancer 1999, 86:1231-9.
221. Claessens JJ, Beerendonk CC, Schattenberg AV. Quality of life, reproduction and sexuality after stem cell transplantation with partially T-cell-depleted grafts and after conditioning with a regimen including total body irradiation. Bone Marrow Transplant 2008, 37:831-6.
222. Humphreys CT, Tallman B, Altmaier EM, Barnette V. Sexual functioning in patients undergoing bone marrow transplantation: A longitudinal study. Bone Marrow Transplant 2007, 39:491-6.
223. Syrjala KL, Langer SL, Abrams JR, Storer BE, Martin PJ. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol 2005, 23:6596-606.
224. Syrjala KL, Kurland BF, Abrams JR, Sanders JE, Heiman JR. Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years. Blood 2008, 111:989-96.
225. Zantomio D, Grigg AP, McGregor L, Panek-Hudson Y, Szer J, Ayton R. Female genital tracet graft-versus-host disease: Incidence, risk factors and recommendations for management. Bone Marrow Transplant 2006, 38:567-72.
226. Brydøy M, Fosså SD, Dahl O, Bjøro T. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol 2007, 46:480-9.
227. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: Who is at risk and what can be offered? Lancet Oncol 2005, 6:209-18.
228. Rutter MM, Rose SR. Long-term endocrine sequelae of childhood cancer. Curr Opin Pediatr 2007, 19:480-7.
229. Zebrack B. Information and service needs for young adult cancer patients. Support Care Cancer 2008, 16:1353-60.
230. Ferrari A, Montello M, Budd T, Bleyer A. The challenges of clinical trials for adolescents and young adults with cancer. Pediatr Blood Cancer 2008, 50(5):1101-4. suppl
231. Relander T, Cavallin-Ståhl E, Garwicz S, Olsson AM, Willén M. Gonadal and sexual function in men treated for childhood cancer. Med Pediatr Oncol 2000, 35:52-63.
232. van Dijk EM, van Dulmen-den Broeder E, Kaspers GJ, van Dam EW, Braam KI, Huisman J. Psychosexual functioning of childhood cancer survivors. Psychooncology 2008, 17:506-11.
233. Underhill K, Operario D, Montgomery P. Abstinence-only programs for HIV infection prevention in high-income countries. Cochrane Database Syst Rev 2007, 17:CD005421.
234. Canada AL, Schover LR, Li Y. A pilot intervention to enhance psychosexual development in adolescents and young adults with cancer. Pediatr Blood Cancer 2007, 49:824-8.
235. Donovan KA, Taliaferro LA, Alvarez Em, Jacobson PB, Roetzheim RG, Wenham RM. Sexual health in women treated for cervical cancer: Characteristics and correlates. Gynecol Oncol 2007, 104:428-34.
236. Lindau ST, Gavrilova N, Anderson D. Sexual Morbidity in very long term survivors of vaginal and cervical cancer; A comparison to national norms. Gynecol Oncol 2007, 106:413-8.
237. Bergmark K, Avall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G. Patient-rating of distressful symptoms after treatment for early cervical cancer. Acta Obstet Gynecol Scand 2002, 81:443-50.
238. Jensen PT, Groenvold M, Klee MC, Thranov I, Petersen MA, Machin D. Early stage cervical carcinoma radical hysterectomy and sexual functioning. Cancer 2004, 100:97-106.
239. Anderson B, Woods X, Copeland L. Sexual self schema and morbidity sexual among gynecological cancer survivors. J Consult Clin Psychol 1997, 65:221-9.
240. Greimel ER, Winter R, Kapp KS, Haas J. Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psychooncology 2009, 18:476-82.
241. Pieterse QD, Ter Kuile MM, DeRuiter MC, Trimbos JBMZ, Kenter GG, Maas CP. Vaginal blood flow after radical hysterectomy with and without nerve sparing. A preliminary report. Int J Gynecol Cancer 2008, 18:576-83.
242. Bergmark K, Avall-Lundqvist E, Dickman P, Henningsohn L, Steinbeck G. Vaginal changes and sexuality in women with a history of cervical Cancer. NEJM 1999, 18:1383-9.
243. Frumovitz M, Schover LR, Munsell MF, Jhingran A, Wharton JT, Eifel P. Quality of life and sexual functioning in cervical cancer survivors. J Clinc Oncol 2005, 23:7428-36.
244. Vistad I, Cvancarova M, Fossa SD, Kristensen GB. Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: How well do physicians' assessments agree with those of their patients? Int J Radiat Oncol Biol Phys 2008, 71:1334-42.
245. Park SY, Bae DS, Nam JH, Park PT, Cho CH, Lee JM, Lee MK, Kim SH, Park SM, Yun YH. Quality of life and sexual problems in disease-free survivors of cervical cancer compared with the general population. Cancer 2007, 110:2716-25.
246. Burns M, Costello J, Ryan-Woolley B, Davidson S. Assessing the impact of late treatment effects in cervical cancer: An exploratory study of women's sexuality. Eur J Cancer Care 2007, 16:364-72.
247. Carmack T, Basen Engguist K, Shinn EH, Bodurka DC. Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol 2004, 22:881-9.
248. Liavaag AH, Dørum A, Bjøro T, Oksefjell H, Fosså SD, Tropé C, Dahl AA. A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. Gynecol Oncol 2008, 108:348-54.
249. Atkins L, Fallowfield L. Fallowfield sexual activity quetionaire in women with, without and at risk for cancer. Menopause Int 2007, 13:103-9.
250. Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D. Reproductive and sexual function after platinum based chemotherapy in long term ovarian germ cell tumor survivors: A gynecology oncology group study. J Clin Oncol 2007, 25:2792-7.
251. Likes WM, Stegbauer C, Tillmanns T, Pruett J. Pilot study of sexual function and quality of life after excision for vulvar intraepithelial neoplasia. J Reprod Med 2007, 52:23-7.
252. Jeffries SA, Robinson JW, Craighead PS, Keats MR. An effective group psychoeducational intervention for improving compliance with vaginal dilation: A randomized controlled trial. Int J Radiat Oncol Biol Phys 2006, 65:404-11.
253. Position statement: The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 Position state of the North American Menopause Society. Menopause 2007, 14:357-69. [No authors listed]
254. Hodis HN, Mack WJ. Postmenopausal hormone therapy and cardiovascular disease in perspective. Clin Obstet Gynecol 2008, 51:564-80.
255. Schroder M, Mell LK, Hurteau JA, Collins YC, Rotmensch J, Wagoner SE. Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients. Int J Radiat Oncol Biol 2005, 61:1078-86.
256. Raspagliesi F, Ditto A, Hanozet F, Martinelli F, Solima E, Zanaboni F, Kusamura S, Fontanelli R. Nerve sparing radical hysterectomy: A surgical technique for preserving the autonomic hypogastric nerve. Gynecol Oncol 2004, 93:307-14.
257. Lagana L, McGarvey EL, Classen C, Koopman C. Psychosexual dysfunction among gynecologic cancer survivors. J Clin Psych Med Set 2001, 8:73-83.
258. Chan JK, Sugiyama V, Tajalli T, Pham H, Gu M, Rutgers J. Conservative clitoral preservation surgery in treatment of vulvar squamous cell carcinoma. Gynecol Oncol 2004, 95:152-6.
259. Plante M, Roy M. Radical tracelectomy. Oper Tech Gynecol Surg 1997, 2:187-99.
260. Gleeson N, Baile W, Roberts W, Hoffman M, Fiorica J, Barton D, Cavanagh D. Surgical and psychosexual outcome following vaginal reconstruction with pelvic exenteration. Eur J Gynaecol Oncol 1994, 15:89-95.
261. Robinson JW. Sexuality and cancer. Breaking the silence. Aust Fam Physician 1998, 27:45-7.
262. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial. J Nat Cancer Inst 2000, 92:1054-64.
263. Zegwaard MI, Gamel CJ, Dugris DJ, Logmans A. The experience of sexuality and information received in women with cervical cancer and their partners. Verpleegkunde 2000, 15:18-27.
264. Brotto J, Heiman J. Mindfulness in sex therapy: Application for women with sexual difficulties following gynecological cancer. Sex Relat Ther 2007, 22:3-11.
265. Brotto LA, Heiman JR, Goff B, Greer B, Lentz GM, Swisher E. A psychoeducational intervention for sexual dysfunction in women with gynecological cancer. Arch Sex Behav 2008, 37:317-29.
266. Amsterdam A, Krychman M. Sexual dysfunction in patients with gynecological neoplasms: A retrospective pilot study. J Sex Med 2006, 3:646-9.
267. Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009, 16:30-6.
268. Devita VT, Rosenberg SA, Hellman S. 6th. Cancer: Principles and practices of oncology 2000, 3032-49. eds., edition, Philadelphia, PA, Lippincott Williams & Wilkins
269. Anderson BL. Surviving cancer: The importance of sexual self-concept. Med Pediatr Oncol 1999, 33:15-23.
270. Fobair P, Stewart SL, Chang S, D'onofrio C, Banks PJ, Bloom JR. Body image and sexual problems in younger women with breast cancer. Psychooncology 2006, 15:579-94.
271. Taylor KL, Lamdan RM, Siegel JE, Shelby R, Hrywna M, Moran-Klimi K. Treatment regime sexual attractiveness concerns and psychological adjustment among African American breast cancer patients. Psychooncology 2002, 11:505-17.
272. Barni S, Mondin R. Sexual dysfunction in treated breast cancer patients. Ann Oncol 1997, 8:149-53.
273. Burwell SR, Case LD, Kaelin C, Avis NE. Sexual problems in younger women after breast cancer surgery. J Clin Oncol 2006, 24:2815-21.
274. Rowland JH, Desmond DA, Meyerowitz BE, Belin TR, Wyatt GE, Ganz PA. Role of breast reconstruction surgery in physical and emotional outcomes among breast cancer survivors. J Natl Cancer Inst 2000, 92:1422-9.
275. Yurek DM, Farrar W, Anderson BL. Breast cancer surgery comparing groups and determining differences in postoperative sexuality and body change stress. J Consult Clin Psychol 2000, 68:697-709.
276. Kornblith AB, Ligibel J. Psychosocial and sexual functioning of survivors of breast cancer. Semin Oncol 2003, 30:799-813.
277. Demark-Wahnefried W, Rimer BK, Winer EP. Weight gain in women diagnosed with breast cancer. J Am Diet Assoc 1997, 97:519-26.
278. Goodwin PJ, Ennis M, Pritchard KI, McCready D, Koo J, Sidlofsky S, Trudeau M, Hood N, Redwood S. Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 1999, 17:120-9.
279. Schover LR, Yetman RJ, Tuason LJ, Meisler E, Esselstyn CB, Hermann RE, Grundfest-Broniatowski S, Dowden RV. Partial mastectomy and breast reconstruction. A comparison of their effects on psychosocial adjustment, body image, and sexuality. Cancer 1995, 75:54-64.
280. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the arimidex, tamoxifen alone or in combination (ATAC) Adjunct Breast Cancer Trial. J Clin Oncol 2004, 22:4261-71.
281. van Oostrom I, Meijers-Heijboer H, Lodder LN, Duivenvoorden HJ, van Gool AR, Seynaeve C, van der Meer CA, Klijn JG, van Geel BN, Burger CW, Wladimiroff JW, Tibben A. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: A 5-year follow-up study. J Clin Oncol 2003, 21:3867-74.
282. Robson M, Hensley M, Barakat R, Brown C, Chi D, Poynor E, Offit K. Quality of life in women at risk for ovarian cancer who have undergone risk reducing oophorectomy. Gynecol Oncol 2003, 89:281-7.
283. Ganz PA, Desmond KA, Belin TR, Meyerowitz BE, Rowland JH. Predictors of sexual health in women after a breast cancer diagnosis. JCO 1999, 17:2371-80.
284. Alder J, Zanetti R, Wight E, Urech C, Fink N, Bitzer J. Sexual dysfunction after premenopausal stage I and II breast cancer: Do androgens play a role? J Sex Med 2008, 5:1898-906.
285. Skouby SO, Al-Azzawi F, Barlow D. European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005, 51:8-14.
286. Kendal A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006, 17:584-7.
287. Labrie F, Cusan L, Gomes J, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008, 111:178-94.
288. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009, 16:907-22.
289. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Balser J. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009, 16:923-31.
290. Barton DL, Wender DB, Sloan JA, Dalton RJ, Balcueva EP, Atherton PJ, Bernath AM, DeKrey WL, Larson T, Bearden JD, Carpenter PC, Loprinzi CL. Randomized clinical trial to evaluate transdermal testosterone in female cancer survivors with decreased libido. North Central Cancer Treatment Group Protocol N02C3. J Natl Cancer Inst 2007, 2007:672-9.
291. Fobair P, Spiegel D. Concerns about sexuality after breast cancer. Cancer J 2009, 15:19-26.
292. Outcomes and quality of life following breast cancer treatment in older women: when, why, how much, and what do women want? Health Qual Life Outcomes. 2003, 1:45.
293. Stead ML, Fallowfield L, Brown JM, Selby P. Communication about sexual problems and sexual concerns in ovarian cancer: Qualitative study. BMJ 2001, 323:836-7.
294. Bruner DW, Boyd CP. Assessing women's sexuality after cancer therapy: Checking assumptions with the focus group technique. Cancer Nurs 1999, 22:438-47.
295. Scott JL, Kayser K. A Review of couple-based interventions for enhancing women's sexual adjustment and body image after cancer. Cancer J 2009, 15:48-56.